For decades, scientists have pursued a central idea in Alzheimer’s disease — that sticky clumps of a protein called amyloid beta are the main cause of memory decline in affected brains. That hypothesis shaped how research was funded, published, and translated into drug development.

But recent investigations suggest that a key pillar of that hypothesis may have been built on faulty and possibly manipulated data, raising serious questions about how Alzheimer’s research was steered — and what opportunities might have been missed along the way.

In 2021–2022, Dr. Matthew Schrag, a neuroscientist and physician at Vanderbilt University, began examining published images from Alzheimer’s studies — initially in part because of concerns about another experimental drug’s claims. In the process, he noticed numerous irregularities in images from a 2006 landmark paper in Nature by researcher Sylvain Lesné.

That paper introduced a specific amyloid variant called Aβ56* and suggested it caused memory loss in rats — a result that seemed to support the amyloid hypothesis and shaped much of the research that followed.

Schrag flagged dozens of images from this and related papers that appeared to show signs of duplication or other inconsistencies — suspicious enough that several independent scientific image analysts and Alzheimer’s researchers later agreed they raised serious concerns about the validity of the visual data being presented.

In response to Schrag’s concerns, Science magazine conducted a six-month examination. Reviewers found evidence suggesting many published images may have been altered “to better fit a hypothesis” — not merely cleaned up or clarified for publication but presented in ways that appeared inconsistent with original experimental results.

By 2024, the original 2006 Nature paper — one of the most cited Alzheimer’s studies of the past two decades with over 2,000 citations — was formally retracted after investigation confirmed manipulated figures.

Why does this matter beyond academic circles? Because that one key paper helped set the research agenda for Alzheimer’s disease for over 15 years, directing funding, publication priority, and clinical trial design. For example:

• Roughly hundreds of millions to billions of dollars in research efforts and funding decisions were influenced by follow-on work from the original findings.
• A large proportion of drugs tested in human clinical trials — including expensive monoclonal antibody therapies — were designed to target amyloid beta pathways derived from this line of research.
• Clinical results have often shown limited benefits for patients, raising questions about whether the focus on amyloid plaque has overshadowed other mechanisms that might be more fruitful.

This case highlights a few critical themes for science and public health:

• Rethinking dominant theories: Over-reliance on a single hypothesis may slow progress by diverting attention from other promising biological processes — such as inflammation, blood vessel health, immune response, and metabolic factors — that may contribute to Alzheimer’s disease.
• The value of replication: Scientific findings must be reproducible to be reliable. Many labs struggled to replicate key features of the original Amyloid Aβ56 results even before the image issues were exposed.

Several amyloid-targeting drugs developed from this research have failed to meaningfully improve cognitive outcomes. Meanwhile, Alzheimer’s prevalence has continued to rise—by an estimated 60–80% over the past two decades—raising important questions about whether current research and treatment strategies are sufficient. Increasing evidence supports Alzheimer’s as a multifactorial condition involving inflammation, metabolic dysfunction, vascular health, environmental exposures, and lifestyle factors.

At our office, we take a comprehensive, evidence-based approach to brain health—looking beyond one pathway to identify modifiable risks and personalized strategies.